Duarte Daniel, Prieto Lourdes Rosa, Suntharos Patcharapong
Department of Pediatric Cardiology, The Heart Program, Nicklaus Children's Hospital, Miami, Florida, USA.
Department of Pediatrics, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.
Ann Pediatr Cardiol. 2022 Mar-Apr;15(2):180-182. doi: 10.4103/apc.apc_71_21. Epub 2022 Aug 19.
Patients with single right ventricle and tricuspid regurgitation have increased morbidity and mortality rates. The outcomes of surgical tricuspid valve repair and replacement are dismal. Although some centers prefer valve replacement with a bioprosthetic valve in the tricuspid position for the pediatric population, these valves have limited longevity and will eventually need to be replaced. Unfortunately, single ventricle patients are fragile and unlikely to tolerate a second replacement. Percutaneous valve-in-valve (ViV) implantation is an acceptable alternative with low morbidity and mortality. Studies have also shown acceptable short- and mid-term outcomes. We report a case of Melody ViV placement in the tricuspid position in a patient with hypoplastic left heart syndrome through the fenestration of a Fontan conduit.
单右心室合并三尖瓣反流的患者发病率和死亡率增加。外科三尖瓣修复和置换的结果不佳。尽管一些中心倾向于在儿童人群中将生物人工瓣膜置换到三尖瓣位置，但这些瓣膜寿命有限，最终仍需更换。不幸的是，单心室患者身体脆弱，不太可能耐受二次置换。经皮瓣中瓣（ViV）植入是一种发病率和死亡率较低的可接受替代方案。研究也显示了可接受的短期和中期结果。我们报告了一例通过Fontan管道开窗将Melody瓣膜ViV植入法洛四联症患者三尖瓣位置的病例。
